discovered that a hedgehog signaling inhibitor (GANT61) could potently suppress the growth of CD44+ sorafenib resistant HCC PDO lines, indicating combination of sorafenib and Hedgehog signaling inhibitor may benefit HCC patients with high CD44 expression (60). The gene discussed is CD44; the disease is hepatocellular carcinoma.